WO2001070728A1 - 2-[nitrogen-heterocyclic]pyrimidone derivatives - Google Patents

2-[nitrogen-heterocyclic]pyrimidone derivatives Download PDF

Info

Publication number
WO2001070728A1
WO2001070728A1 PCT/EP2001/003639 EP0103639W WO0170728A1 WO 2001070728 A1 WO2001070728 A1 WO 2001070728A1 EP 0103639 W EP0103639 W EP 0103639W WO 0170728 A1 WO0170728 A1 WO 0170728A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
ring
ylpyrimidin
piperazin
group
Prior art date
Application number
PCT/EP2001/003639
Other languages
French (fr)
Inventor
Antonio Almario Garcia
Ryoichi Ando
Jonathan Reid Frost
Adrien Tak Li
Aya Shoda
Original Assignee
Sanofi-Synthelabo
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00400802A external-priority patent/EP1136489A1/en
Priority claimed from EP00400803A external-priority patent/EP1136493A1/en
Priority claimed from EP00400801A external-priority patent/EP1136483A1/en
Application filed by Sanofi-Synthelabo, Mitsubishi Pharma Corporation filed Critical Sanofi-Synthelabo
Priority to AU2001262150A priority Critical patent/AU2001262150A1/en
Publication of WO2001070728A1 publication Critical patent/WO2001070728A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal activity of GSK3 ⁇ .
  • GSK3 ⁇ (glycogen synthase kinase 3 ⁇ ) is a proline directed serine, threonine kinase that plays an important role in the control of metabolism, differentiation and survival. It was initially identified as an enzyme able to phosphorylate and hence inhibit glycogen synthase. It was later recognized that GSK3 ⁇ was identical to tau protein kinase 1 (TPK1), an enzyme that phosphorylates tau protein in epitopes that are also found to be hyperphosphorylated in Alzheimer's disease and in several taupathies.
  • TPK1 tau protein kinase 1
  • GSK3 ⁇ protein kinase B phosphorylation results in a loss of its kinase activity, and it has been hypothesized that this inhibition may mediate some of the effects of neurotrophic factors.
  • inhibition of GSK3 ⁇ activity may result in neurotrophic activity.
  • GSK3 ⁇ may be the link between the two major pathological processes in Alzheimer's disease: abnormal APP (Amyloid Precursor Protein) processing and tau protein hyperphosphorylation.
  • tau hyperphosphorylation results in a destabilization of the neuronal cytoskeleton
  • the pathological consequences of abnormal GSK3 ⁇ activity are, most likely, not only due to a pathological phosphorylation of tau protein because, as mentioned above, an excessive activity of this kinase may affect survival through the modulation of the expression of apoptotic and antiapoptotic factors.
  • ⁇ -amyloid-induced increase in GSK3 ⁇ activity results in the phosphorylation and, hence the inhibition of pyruvate dehydrogenase, a pivotal enzyme in energy production and acetylcholine synthesis.
  • GSK3 ⁇ may find application in the treatment of the neuropathological consequences and the cognitive and attention deficits associated with Alzheimer's disease, as well as other acute and chronic neurodegenerative diseases.
  • these include, in a non- limiting manner, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma.
  • tauopathies e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy
  • vascular dementia e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy
  • cerebrovascular accidents e.g. age related macular degeneration
  • GSK3 ⁇ may find application in the treatment of other diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
  • diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
  • R represents a 2,6-dichlorobenzyl group, a 2-(2-chlorophenyl)ethylamino group, a 3-phenylpropylamino group, or a 1-methyl-3-phenylpropylamino group.
  • the compounds represented by formula (A) are characterized by a 4-fluorophenyl group at the 5-position of the pyrimidine ring.
  • the main pharmacological activity disclosed for the compounds represented by formula (A) is an anti-inflammatory effect, whereas the compounds of the present invention represented by formula (I) herein below are useful as GSK3 ⁇ inhibitors or as medicaments for the therapeutic treatment of neurodegenerative diseases, and therefore, their pharmacological activities are totally different.
  • An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3 ⁇ activity, more particularly of neurodegenerative diseases. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables prevention and/or treatment of the neurodegenerative diseases such as Alzheimer's disease.
  • the inventors of the present invention have identified compounds possessing inhibitory activity against GSK3 ⁇ . As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases.
  • the present invention thus provides pyrimidone derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof:
  • R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C 1 - 4 alkyl group, C 1 - 4 alkoxy group or a halogen atom;
  • R2 represents
  • heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or
  • n 1 or 2;
  • Z being selected from the group consisting of :
  • R3 represents a hydrogen atom or a C 1 - 6 alkyl group
  • the C- 6,10 aryl groups and heterocyclic ring being optionally substituted by 1 to 3 substituents selected from a C ⁇ . 6 alkyl group, halogen atom, a C 1-2 perhalogenated alkyl group, a C ⁇ . 3 halogenated alkyl group, a hydroxyl group, a C 1 . 6 alkoxy group, methylenedioxy group, a nitro, a cyano or a phenyl group.
  • a medicament comprising as an active ingredient a substance selected from the group consisting of the pyhmidone derivatives represented by formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof.
  • the aforementioned medicament which is used for preventive and/or therapeutic treatment of diseases caused by abnormal GSK3 ⁇ activity
  • the aforementioned medicament which is used for preventive and/or therapeutic treatment of neurodegenerative diseases and in addition other diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
  • the aforementioned medicament wherein the diseases are neurodegenerative diseases and are selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma, and the aforementioned medicament in the form of pharmaceutical composition containing the above substance as an active ingredient together with one or more pharmaceutical additives.
  • Alzheimer's disease Parkinson's disease
  • tauopathies e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy
  • other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retin
  • the present invention further provides an inhibitor of GSK3 ⁇ activity comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the salts thereof, and the solvates thereof and the hydrates thereof.
  • a method for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal GSK3 ⁇ activity which comprises the step of administering to a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof; and a use of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof for the manufacture of the aforementioned medicament.
  • the C ⁇ _ 6 alkyl group represents a straight or branched alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n- propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert- butyl group, n-pentyl group, isopentyl group, neopentyl group, 1 ,1-dimethylpropyI group, n-hexyl group, isohexyl group, and the like;
  • the C 3 .6 cycloalkyl group represents a cyclic alkyl group of 3 to 6 carbon atoms, for example, cyclopropyl, 2-methyl cyclopropyl, 2-ethyl cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl, and the like;
  • the C ⁇ -6 alkoxy group represents an alkyloxy group having 1 to 6 carbon atoms for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group, neopentyloxy group, 1 ,1-dimethylpropyloxy group;
  • the halogen atom represents a fluorine, chlorine, bromine or iodine atom
  • the C1-2 perhalogenated alkyl group represents an alkyl group wherein all the hydrogen have been substituted by a halogen atom, for example a CF 3 or C 2 F 5 ;
  • the Ci. 3 halogenated alkyl group represents an alkyl group wherein at least one hydrogen has not been substituted by a halogen atom
  • the C ⁇ .io aryl group represents a phenyl group, 1-naphthyl group, 2- naphthyl group and tetrahydronaphthyl group;
  • the heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10 represents a furan ring, dihydrofuran ring, tetrahydrofuran ring, pyran ring, dihydropyran ring, tetrahydropyran ring, benzofuran ring, furopyridine ring, isobenzofuran ring, chromene ring, chroman ring, isochroman ring, thiophene ring, benzothiophene ring, thienopyridine ring, pyrrole ring, pyrroline ring, pyrrolidine ring, imidazole ring, imidazoline ring, imidazolidine ring, imidazopyridine ring, pyrazole ring, pyrazoline ring, pyrazolidine ring, triazole ring, tetrazole ring,
  • the compounds represented by the aforementioned formula (I) may form a salt.
  • the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, N,N- bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N- methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, ⁇ -hydroxylysine, and arginine.
  • the base-addition salts of acidic compounds are prepared by standard procedures well known in the art.
  • examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, acetic acid, propionic acid, tarta c acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid.
  • mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid
  • organic acids such as methanesulfonic acid, benzenesulfonic acid, p- tolu
  • the acid-addition salts of the basic compounds are prepared by standard procedures well know in the art which include, but are not limited thereto, dissolving the free base in an aqueous alcohol solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and an acid in an organic solvent, in which case the salt separates directly, or is precipitated with a second organic solvent, or can be obtained by concentration of the solution.
  • the acids which can be used to prepare the acid-addition salts include preferably those which produce, when combined with the free base, pharmaceutically-acceptable salts, that is, salts whose anions are relatively innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not compromised by side effects ascribable to the anions.
  • pharmaceutically-acceptable salts that is, salts whose anions are relatively innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not compromised by side effects ascribable to the anions.
  • the pyrimidone derivatives represented by the aforementioned formula (I) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the pyrimidone derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers in pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention.
  • 1 H-4-one compound of may exist as tautomers.
  • the existence of such tautomers is readily apparent to those skilled in the art, and these tautomers fall within the scope of the present invention.
  • Preferred compounds of the present invention represented by formula (I) include also:
  • R1 represents a 3- or 4-pyridyl group and more preferably 4-pyridyl group, which may be substituted by a C ⁇ - 2 alkyl group, C ⁇ . 2 alkoxy group or a halogen atom;
  • More preferred compounds of the present invention represented by formula (I) include also:
  • R1 represents an unsubstituted 4-pyridyl group
  • Particularly preferred compounds of the present invention represented by formula (I) include:
  • the present invention concerns also methods for preparing the pyrimidone compounds represented by the aforementioned formula (I).
  • R represents an alkyl group, which may be substituted, and definitions of R1 , R2 and n are the same as those already described above for compound of formula (I)).
  • the 3-ketoester represented by the above formula (II) is allowed to react with the compound represented by formula (III) or a salt thereof to obtain the compound of the aforementioned formula(l) in the presence of a base such as lithium tert- butoxide, sodium tert-butoxide, potassium tert-butoxide, lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide, sodium ethoxide, potassium ethoxide, 1 ,8-diazabicyclo[5,4,0]undec-7-ene, triethylamine, diisopropyl- ethylamine, dimethylbenzylamine, dimethylaniline, diethylaniline and the like.
  • a base such as lithium tert- butoxide, sodium tert-butoxide, potassium tert-butoxide, lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide, sodium ethoxide,
  • a solvent suitable for the reaction examples include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbon solvents such as benzene, toluene, xylene; halogenated solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N- methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide and the like.
  • alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol
  • etheric solvents such as die
  • a single solvent or a mixture of two or more solvents may be used depending on the base used, and the reaction may be carried out for 1 hour to 14 days at a suitable temperature ranging from 0° to 250°C under nitrogen or argon atmosphere or in ordinary air.
  • compounds of formula (II), wherein R1 represent a 4-pyridyl group optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or a halogen atom can be prepared by reacting a nicotinic acid optionally substituted by a alkyl group, C 1 . 4 alkoxy group or an halogen, with a malonic acid monoester.
  • the reaction can be carried out using methods well known to one skilled in the art, such as for example in presence of a coupling agent such as 1 ,1 '-carbonylbis-1 H- imidazole in a solvent such as a tetrahydrofuran at a temperature ranging from 20 to 70°C.
  • pyrimidone compounds represented by the aforementioned formula (I) may be prepared according to scheme 2.
  • the 3-ketoester of formula (II) is allowed to react with a 2-methyl-2-thiopseudourea sulfate.
  • the reaction may be carried out in solvent such as water or an alcohol, such as ethanol, propanol and butanol, at a suitable temperature ranging from 25-100°C under ordinary air.
  • compound of formula (I) can be derivatised into other compound of formula (I), using well known methods in the art, for example when the C 6 , ⁇ o aryl groups or the heterocyclic ring is substituted by a hydroxyl group, the hydroxyl group can be alkylated to give a Ci- ⁇ alkoxy group.
  • protection or deprotection of a functional group may sometimes be necessary.
  • a suitable protecting group can be chosen depending on the type of a functional group, and a method described in the literature may be applied. Examples of protecting groups, of protection and deprotection methods are given for example in Protective groups in Organic Synthesis Greene et al., 2nd Ed. (John Wiley & Sons, Inc., New York).
  • the compounds of the present invention have inhibitory activity against GSK3 ⁇ . Accordingly, the compounds of the present invention are useful as an active ingredient for the preparation of a medicament, which enables preventive and/or therapeutic treatment of a disease caused by abnormal GSK3 ⁇ activity and more particularly of neurodegenerative diseases such as Alzheimer's disease. In addition, the compounds of the present invention are also useful as an active ingredient for the preparation of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g.
  • Parkinson's disease tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g.
  • age related macular degeneration brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma; and other diseases such as non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
  • diseases such as non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
  • the present invention further relates to a method for treating neurodegenerative diseases caused by abnormal activity of GSK3 ⁇ and of the aforementioned diseases which comprises administering to a mammalian organism in need thereof an effective amount of a compound of the formula (I).
  • a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof.
  • the substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives.
  • a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives.
  • two or more of the aforementioned substances may be used in combination.
  • the above pharmaceutical composition may be supplemented with an active ingredient of another medicament for the treatment of the above mentioned diseases.
  • a type of the pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration.
  • the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like.
  • Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally.
  • Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art.
  • Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives.
  • the pharmaceutical additives may be incorporated in a ratio ranging from 1 % by weight to 90% by weight based on the weight of an active ingredient.
  • excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like.
  • a conventional inert diluent such as water or a vegetable oil may be used.
  • the liquid composition may contain, in addition to the inert diluent, auxiliaries such as moistening agents, suspension aids, sweeteners, aromatics, colorants, and preservatives.
  • the liquid composition may be filled in capsules made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g.
  • injections, suppositories include water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like.
  • base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol.
  • Dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like.
  • a daily dose for oral administration to an adult may be 0.01 to 1 ,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days.
  • administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.
  • Example 1 Preparation of 2-[4-(R2 substitutent)piperazin-1-yl]-6-pyridin-4- ylpyrimidin-4(1 H)-one.
  • R1 4-pyridyl
  • Test Example Inhibitory activity of the medicament of the present invention against GSK3 ⁇ :
  • a first protocol 7.5 ⁇ M of prephosphorylated GS1 peptide and 10 ⁇ M ATP (containing 300,000 cpm of 33P-ATP) were incubated in 25 mM Tris-HCI, pH 7.5, 0.6 mM DTT, 6 mM MgCI 2 , 0.6 mM EGTA, 0.05 mg/ml BSA buffer for 1 hour at room temperature in the presence of GSK3 ⁇ (total reaction volume : 100 microliters).
  • the reaction was stopped with 100 microliters of a solution made of 25 g polyphosphoric acid (85% P 2 O 5 ), 126 ml 85% H 3 PO 4 , H 2 O to 500 ml and then diluted to 1 :100 before use. An aliquot of the reaction mixture was then transferred to Whatman P81 cation exchange filters and rinsed with the solution described above. Incorporated 33P radioactivity was determined by liquid scintillation spectrometry.
  • the phosphorylated GS-1 peptide had the following sequence : NH2-YRRAAVPPSPSLSRHSSPHQS(P)EDEE-COOH.
  • the GSK3 ⁇ inhibitory activity of the compounds of the present invention are expressed in IC 50 , and as an illustration the range of ICso's for the compound in the table 1 is between 0.1 to 10 micromolar concentrations.
  • the compounds of the present invention have GSK3 ⁇ inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activity of GSK3 ⁇ and more particularly of neurodegenerative diseases.

Abstract

A pyrimidone derivative represented by formula (I) or a salt thereof wherein: R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or a halogen atom; (a) represents a [nitrogen-heterocyclic ring] of formula (X), (Y) or (Z). And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease.

Description

SPECIFICATION
2-[NITROGEN-HETEROCYCLIC]PYRIMIDONE DERIVATIVES
Technical Field
The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal activity of GSK3β.
Background Art
GSK3β (glycogen synthase kinase 3β) is a proline directed serine, threonine kinase that plays an important role in the control of metabolism, differentiation and survival. It was initially identified as an enzyme able to phosphorylate and hence inhibit glycogen synthase. It was later recognized that GSK3β was identical to tau protein kinase 1 (TPK1), an enzyme that phosphorylates tau protein in epitopes that are also found to be hyperphosphorylated in Alzheimer's disease and in several taupathies. Interestingly, protein kinase B (AKT) phosphorylation of GSK3β results in a loss of its kinase activity, and it has been hypothesized that this inhibition may mediate some of the effects of neurotrophic factors. Moreover, phosphorylation by GSK3β of β-catenin, a protein involved in cell survival, results in its degradation by an ubiquitinilation dependent proteasome pathway. Thus, it appears that inhibition of GSK3β activity may result in neurotrophic activity. Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3β, enhances neuritogenesis in some models and also increases neuronal survival, through the induction of survival factors such as Bcl-2 and the inhibition of the expression of proapoptotic factors such as P53 and Bax. Recent studies have demonstrated that β-amyloid increases the GSK3β activity and tau protein phosphorylation. Moreover, this hyperphosphorylation as well as the neurotoxic effects of β-amyloid are blocked by lithium chloride and by a GSK3β antisense mRNA. These observations strongly suggest that GSK3β may be the link between the two major pathological processes in Alzheimer's disease: abnormal APP (Amyloid Precursor Protein) processing and tau protein hyperphosphorylation.
Although tau hyperphosphorylation results in a destabilization of the neuronal cytoskeleton, the pathological consequences of abnormal GSK3β activity are, most likely, not only due to a pathological phosphorylation of tau protein because, as mentioned above, an excessive activity of this kinase may affect survival through the modulation of the expression of apoptotic and antiapoptotic factors. Moreover, it has been shown that β-amyloid-induced increase in GSK3β activity results in the phosphorylation and, hence the inhibition of pyruvate dehydrogenase, a pivotal enzyme in energy production and acetylcholine synthesis.
Altogether these experimental observations indicate that GSK3β may find application in the treatment of the neuropathological consequences and the cognitive and attention deficits associated with Alzheimer's disease, as well as other acute and chronic neurodegenerative diseases. These include, in a non- limiting manner, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma.
In addition GSK3β may find application in the treatment of other diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
PCT application WO 98/24782 discloses compounds represented by the following formula (A):
Figure imgf000004_0001
(A) wherein R represents a 2,6-dichlorobenzyl group, a 2-(2-chlorophenyl)ethylamino group, a 3-phenylpropylamino group, or a 1-methyl-3-phenylpropylamino group. The compounds represented by formula (A) are characterized by a 4-fluorophenyl group at the 5-position of the pyrimidine ring. The main pharmacological activity disclosed for the compounds represented by formula (A) is an anti-inflammatory effect, whereas the compounds of the present invention represented by formula (I) herein below are useful as GSK3β inhibitors or as medicaments for the therapeutic treatment of neurodegenerative diseases, and therefore, their pharmacological activities are totally different.
Disclosure of the Invention
An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3β activity, more particularly of neurodegenerative diseases. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables prevention and/or treatment of the neurodegenerative diseases such as Alzheimer's disease. Thus, the inventors of the present invention have identified compounds possessing inhibitory activity against GSK3β. As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases.
The present invention thus provides pyrimidone derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof:
Figure imgf000007_0001
(I) wherein:
R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or a halogen atom;
represents a [nitrogen-heterocyclic ring] of formula X, Y or Z
Figure imgf000007_0002
Figure imgf000007_0003
X Y z Wherein
R2 represents
* a C-6,10 aryl group,
* a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or
* a C1-6 alkyl group substituted by 1 to 3 substituents selected from
- a hydroxyl group,
- a C3.6 cycloalkyl group
- a Cδ.io aryl group and - a heterocyclic ring as defined above; and n represents 1 or 2; Z being selected from the group consisting of :
Figure imgf000008_0001
wherein R3 represents a hydrogen atom or a C1-6 alkyl group;
the C-6,10 aryl groups and heterocyclic ring being optionally substituted by 1 to 3 substituents selected from a Cι.6 alkyl group, halogen atom, a C1-2 perhalogenated alkyl group, a Cι.3 halogenated alkyl group, a hydroxyl group, a C1.6 alkoxy group, methylenedioxy group, a nitro, a cyano or a phenyl group.
According to another aspect of the present invention, there is provided a medicament comprising as an active ingredient a substance selected from the group consisting of the pyhmidone derivatives represented by formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof. As preferred embodiments of the medicament, there are provided the aforementioned medicament which is used for preventive and/or therapeutic treatment of diseases caused by abnormal GSK3β activity, and the aforementioned medicament which is used for preventive and/or therapeutic treatment of neurodegenerative diseases and in addition other diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
As further preferred embodiments of the present invention, there are provided the aforementioned medicament wherein the diseases are neurodegenerative diseases and are selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma, and the aforementioned medicament in the form of pharmaceutical composition containing the above substance as an active ingredient together with one or more pharmaceutical additives.
The present invention further provides an inhibitor of GSK3β activity comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the salts thereof, and the solvates thereof and the hydrates thereof.
According to further aspects of the present invention, there are provided a method for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal GSK3β activity, which comprises the step of administering to a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof; and a use of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof for the manufacture of the aforementioned medicament.
As used herein the Cι_6 alkyl group represents a straight or branched alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n- propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert- butyl group, n-pentyl group, isopentyl group, neopentyl group, 1 ,1-dimethylpropyI group, n-hexyl group, isohexyl group, and the like;
The C3.6 cycloalkyl group represents a cyclic alkyl group of 3 to 6 carbon atoms, for example, cyclopropyl, 2-methyl cyclopropyl, 2-ethyl cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl, and the like;
The Cι-6 alkoxy group represents an alkyloxy group having 1 to 6 carbon atoms for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group, neopentyloxy group, 1 ,1-dimethylpropyloxy group;
The halogen atom represents a fluorine, chlorine, bromine or iodine atom;
The C1-2 perhalogenated alkyl group represents an alkyl group wherein all the hydrogen have been substituted by a halogen atom, for example a CF3 or C2F5;
The Ci.3 halogenated alkyl group represents an alkyl group wherein at least one hydrogen has not been substituted by a halogen atom;
The Cδ.io aryl group represents a phenyl group, 1-naphthyl group, 2- naphthyl group and tetrahydronaphthyl group;
The heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10 represents a furan ring, dihydrofuran ring, tetrahydrofuran ring, pyran ring, dihydropyran ring, tetrahydropyran ring, benzofuran ring, furopyridine ring, isobenzofuran ring, chromene ring, chroman ring, isochroman ring, thiophene ring, benzothiophene ring, thienopyridine ring, pyrrole ring, pyrroline ring, pyrrolidine ring, imidazole ring, imidazoline ring, imidazolidine ring, imidazopyridine ring, pyrazole ring, pyrazoline ring, pyrazolidine ring, triazole ring, tetrazole ring, pyridine ring, pyridine oxide ring, piperidine ring, pyrazine ring, piperazine ring, pyrimidine ring, pyhdazine ring, indolizine ring, indole ring, indoline ring, isoindole ring, isoindoline ring, indazole ring, benzimidazole ring, purine ring, quinolizine ring, quinoline ring, isoquinoline ring, phthalazine ring, naphthyridine ring, quinoxaline ring, quinazoline ring, cinnoline ring, pteridine ring, oxazole ring, oxazolidine ring, isoxazole ring, isoxazolidine ring, thiazole ring, benzothiazole ring, thiazylidine ring, isothiazole ring, isothiazolidine ring, dioxane ring, dithian ring, morpholine ring, thiomorpholine ring, phthalimide ring and the like.
The compounds represented by the aforementioned formula (I) may form a salt. Examples of the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, N,N- bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N- methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, δ-hydroxylysine, and arginine. The base-addition salts of acidic compounds are prepared by standard procedures well known in the art.
When a basic group exists, examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, acetic acid, propionic acid, tarta c acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid.
The acid-addition salts of the basic compounds are prepared by standard procedures well know in the art which include, but are not limited thereto, dissolving the free base in an aqueous alcohol solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and an acid in an organic solvent, in which case the salt separates directly, or is precipitated with a second organic solvent, or can be obtained by concentration of the solution. The acids which can be used to prepare the acid-addition salts include preferably those which produce, when combined with the free base, pharmaceutically-acceptable salts, that is, salts whose anions are relatively innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not compromised by side effects ascribable to the anions. Although medicinally acceptable salts of the basic compounds are preferred, all acid-addition salts are within the scope of the present invention.
In addition to the pyrimidone derivatives represented by the aforementioned formula (I) and salts thereof, their solvates and hydrates also fall within the scope of the present invention. The pyrimidone derivatives represented by the aforementioned formula (I) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the pyrimidone derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers in pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention.
Furthermore, as the pyrimidone derivatives represented by the aforementioned formula (I), a 3H-4-one compound, a 4-hydroxy compound, and a
1 H-4-one compound of may exist as tautomers. The existence of such tautomers is readily apparent to those skilled in the art, and these tautomers fall within the scope of the present invention.
Examples of preferred compounds of the present invention are shown in tables hereinafter. However, the scope of the present invention is not limited by these compounds. Preferred compounds of the present invention represented by formula (I) include also:
(1) Compounds wherein R1 represents a 3- or 4-pyridyl group and more preferably 4-pyridyl group, which may be substituted by a Cι-2 alkyl group, Cι.2 alkoxy group or a halogen atom;
(2) When the [nitrogen-heterocyclic ring] is of formula X, compounds wherein R2 represents * a C6,ιo aryl group, * a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or * a C 1-6 alkyl group substituted by one Cβ.io aryl group.
More preferred compounds of the present invention represented by formula (I) include also:
(1) Compounds wherein R1 represents an unsubstituted 4-pyridyl group;
(2) When the [nitrogen-heterocyclic ring] is of formula X : a) Compounds wherein R2 represents a phenyl or substituted phenyl ring, a naphthyl or substituted naphthyl ring or a tetrahydronaphthyl or a substituted tetrahydronaphthyl ring, or b) Compounds wherein R2 represents a heterocyclic ring selected from furopyridine ring, thienopyridine ring, imidazopyridine ring, pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, isoquinoline ring and pyrimidine ring; and more preferably furo[3,2-c]pyridine ring, thieno[3,2-c]pyridine ring, imidazo[4,5-c]pyridine ring, imidazo[1 ,2-a]pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, isoquinoline ring, pyridine ring and pyrimidine ring, and / or c) Compounds wherein n is 1 ;
(3) When the [nitrogen-heterocyclic ring] is of formula Y, compounds wherein R2 represents a heterocyclic ring selected from a furan ring, imidazole ring, and indoline ring; (4) When the [nitrogen-heterocyclic ring] is of formula Z, compounds wherein the [nitrogen-heterocyclic ring] is selected from : 2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indole,
1 ,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrothieno[2,3-c]pyridine, and 1 ,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine;
(5) Compounds wherein R1 is as defined under (1) and the [nitrogen-heterocyclic ring] and eventually R2 are as defined under (2), (3) or (4).
Particularly preferred compounds of the present invention represented by formula (I) include:
2-[4-(2,5-dimethylphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(7-ethoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(7-methoxy-1 ,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]-6-pyridin-4- ylpyrimidin-4(1 H)-one,
2-[4-(4-methoxyphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(4-chlorophenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(pyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(7-fluoronaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(7-propoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-[7-(2-methylethoxy)naphth-1-yI]piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)- one, 2-[4-(pyrimidin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(2-phenylphenyl)piperazin-1 -yl]-6-pyhdin-4-ylpyrimidin-4(1 H)-one, 2-[4-(phenylmethyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(phenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-[3,4-(methylenedioxy)phenyl]piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(3-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(quinolin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(imidazo[1 ,2-a]pyridin-5-yl)piperazin-1-yl]-6-pyhdin-4-ylpyhmidin-4(1 H)-one, 2-[4-(1 H -indazol-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(5-methoxy-1 H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]-6-pyhdin-4-ylpyrimidin-4(1 H)-one, 2-[4-(1 IH-indazol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(4-methoxy-1 H-benzimidazol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin- 4(1 H)-one, 2-[4-(1 H-indol-5-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(6,7-dimethoxy-1 ,2,3,4-tetrahydronaphthalen-2-yl)piperazin-1-yl]-6-pyridin-4- ylpyrimidin-4( 1 H)-one,
2-[4-(3-phenylpropyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(isoquinolin-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one,
2-[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(4-cyanopyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(2,3-dihydro-1 H-indol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one. 2-[4-(1-methyl-1 H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one,
2-[4-[phenylmethyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1JH)-one,
2-[4-[(4-methoxyphenyl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one,
2-[4-(2-phenyIethyl)piperidin-1-yl]-6-pyridin-4-ylpyhmidin-4(1 H)-one, 2-[4-[hydroxy(furan-2-yl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(2-cyclohexylpropyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(1 H-imidazol-4-yl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(phenylmethyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(1 H-indol-3-yl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(indolin-5-yl)piperidinyl]-6-pyridin-4-ylpyrimidin-4(1 H)-one,
6-pyridin-4-yl-2-[2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indol-2-yl]pyrimidin-4(1H)-one, 6-pyridin-4-yl-2-[1 ,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1 H)-one, 6-pyridin-4-yl-2-[6,7-dimethoxy-1 ,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1 H)- one, 6-pyridin-4-yl-2-[4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl]pyrimidin-4(1 H)-one and
6-pyhdin-4-yl-2-[1 ,2,3,4-tetrahydrobenzofuro[2,3-c]pyhdin-2-yl]pyrimidin-4(1 H)- one.
As a further object, the present invention concerns also methods for preparing the pyrimidone compounds represented by the aforementioned formula (I).
These compounds can be prepared, for example, according to methods explained below.
When the [nitrogen-heterocyclic ring] is of formula X, compounds of formula (I) may prepared according to preparation method 1.
1. Preparation Method 1 scheme 1
Figure imgf000015_0001
X
(ID (III) (i)
(In the above scheme, R represents an alkyl group, which may be substituted, and definitions of R1 , R2 and n are the same as those already described above for compound of formula (I)).
The 3-ketoester represented by the above formula (II) is allowed to react with the compound represented by formula (III) or a salt thereof to obtain the compound of the aforementioned formula(l) in the presence of a base such as lithium tert- butoxide, sodium tert-butoxide, potassium tert-butoxide, lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide, sodium ethoxide, potassium ethoxide, 1 ,8-diazabicyclo[5,4,0]undec-7-ene, triethylamine, diisopropyl- ethylamine, dimethylbenzylamine, dimethylaniline, diethylaniline and the like.
Examples of a solvent suitable for the reaction include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbon solvents such as benzene, toluene, xylene; halogenated solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N- methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide and the like. Generally, a single solvent or a mixture of two or more solvents may be used depending on the base used, and the reaction may be carried out for 1 hour to 14 days at a suitable temperature ranging from 0° to 250°C under nitrogen or argon atmosphere or in ordinary air.
Compounds of formula (II) and formula (III) are commercially available or may be synthesized according to known methods of one skilled in the art.
For example compounds of formula (II), wherein R1 represent a 4-pyridyl group optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or a halogen atom, can be prepared by reacting a nicotinic acid optionally substituted by a
Figure imgf000016_0001
alkyl group, C1.4 alkoxy group or an halogen, with a malonic acid monoester. The reaction can be carried out using methods well known to one skilled in the art, such as for example in presence of a coupling agent such as 1 ,1 '-carbonylbis-1 H- imidazole in a solvent such as a tetrahydrofuran at a temperature ranging from 20 to 70°C.
2. Preparation method 2
Alternatively pyrimidone compounds represented by the aforementioned formula (I) may be prepared according to scheme 2.
Scheme 2
Figure imgf000016_0002
(IV) (V) (I)
(In the above scheme the definition of R1 is the same as already described above). The 2-methylthio derivative represented by the above formula (IV), wherein R2 is as defined for compound of formula (I), is allowed to react with an amine of formula (V) to obtain the compound of the aforementioned formula (I). The reaction may be carried out in a solvent such as, for example, an alcoholic solvent such as n-pentanol or isoamyl alcohol at a suitable temperature ranging from 100 to180 °C under ordinary air.
Compound of formula (IV) may be prepared according to the method defined in scheme 3. Scheme 3
Figure imgf000017_0001
(In the above scheme the definition of R and R1 are the same as those already described above).
According to this method, the 3-ketoester of formula (II) is allowed to react with a 2-methyl-2-thiopseudourea sulfate. The reaction may be carried out in solvent such as water or an alcohol, such as ethanol, propanol and butanol, at a suitable temperature ranging from 25-100°C under ordinary air.
Compounds of formula (V) are commercially available or may be synthesized according to well-known methods of one skilled in the art.
In addition when applicable, compound of formula (I) can be derivatised into other compound of formula (I), using well known methods in the art, for example when the C6,ιo aryl groups or the heterocyclic ring is substituted by a hydroxyl group, the hydroxyl group can be alkylated to give a Ci-β alkoxy group.
In the above reactions, protection or deprotection of a functional group may sometimes be necessary. A suitable protecting group can be chosen depending on the type of a functional group, and a method described in the literature may be applied. Examples of protecting groups, of protection and deprotection methods are given for example in Protective groups in Organic Synthesis Greene et al., 2nd Ed. (John Wiley & Sons, Inc., New York).
The compounds of the present invention have inhibitory activity against GSK3β. Accordingly, the compounds of the present invention are useful as an active ingredient for the preparation of a medicament, which enables preventive and/or therapeutic treatment of a disease caused by abnormal GSK3β activity and more particularly of neurodegenerative diseases such as Alzheimer's disease. In addition, the compounds of the present invention are also useful as an active ingredient for the preparation of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma; and other diseases such as non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
The present invention further relates to a method for treating neurodegenerative diseases caused by abnormal activity of GSK3β and of the aforementioned diseases which comprises administering to a mammalian organism in need thereof an effective amount of a compound of the formula (I).
As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. The substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives. As the active ingredient of the medicament of the present invention, two or more of the aforementioned substances may be used in combination. The above pharmaceutical composition may be supplemented with an active ingredient of another medicament for the treatment of the above mentioned diseases. A type of the pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration. For example, the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally.
Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art. Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives. Generally, the pharmaceutical additives may be incorporated in a ratio ranging from 1 % by weight to 90% by weight based on the weight of an active ingredient.
Examples of excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like. For the preparation of liquid compositions for oral administration, a conventional inert diluent such as water or a vegetable oil may be used. The liquid composition may contain, in addition to the inert diluent, auxiliaries such as moistening agents, suspension aids, sweeteners, aromatics, colorants, and preservatives. The liquid composition may be filled in capsules made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g. injections, suppositories, include water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like. Examples of base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol.
Dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1 ,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.
Chemical Examples
The present invention will be explained more specifically with reference to the following general examples, however, the scope of the present invention is not limited to these examples.
Example 1 : Preparation of 2-[4-(R2 substitutent)piperazin-1-yl]-6-pyridin-4- ylpyrimidin-4(1 H)-one.
1.1. Preparation of Ethyl 3-(4-pyridyl)-3-oxopropionate
Isonicotinic acid (35.56 g, 289 mmol) was added to a solution of 1 ,1'-carbonylbis- 1 H-imidazo!e (46.98 g, 290 mmol) in tetrahydrofuran (700ml), and the resulting solution was stirred for 1.5 hr at 50°C. After cooling to room temperature, malonic acid monoester potassium salt (51.7 g, 304 mmol) and magnesium chloride (34.33 g, 361 mmol) were added, and the mixture was refluxed for 1 hr and then heated at 50°C for 6 hr. The solvent was removed under reduced pressure and the residue was quenched by the addition of dilute acetic acid. The organic layer was extracted with ethyl acetate (3 times) and the combined extracts were washed with dilute aqueous sodium bicarbonate and brine, and were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent ; hexane/ethyl acetate = 2/1 to 1/1) and recrystallization from hexane - ethyl acetate gave 41.52 g (74%) of the title compound.
1.2. Preparation of 2-[4-(R2 substitutent)piperazin-1-yl]-6-pyridin-4-ylpyrimidin- 4(1 H)-one.
Ethyl 3-(4-pyridyl)-3-oxopropionate (0.60g ; 3.1 mmol), 1-amidino-4-(R1 substitutent)piperazine hydrochloride (3.4 mmol) and potassium carbonate (1.15g ; 8.3mmol ) were added to 5 ml of ethanol, and the mixture was heated under reflux at 75° for 20 hours. Acetic acid was added to the reaction mixture , and the solvent was removed by distillation. The residue was treated with water and then with acetic acid , and the resulting solid was separated by filtration, washed with water and ethyl acetate, and dried to obtain the desired compound.
2. Example 2 : Preparation of 2-[heteroaminocyclic]-6-pyridin-4-yl pyrimidin- 4(1 H)-one
2.1. 2-(Methylthio)-6-pyridinyl-4-ylpyrimidin-4(1 H)-one
To a solution of 5.76 g (20.7 mmol) of 2-methyl-2-thiopseudoiurea sulfate in 48 ml of water was added 4.85 g (86.52 mmol) of potassium hydroxide. The mixture was agitated and 8.0 g (41.4 mmol) of ethyl 3-(4-pyridyl)-3-oxopropionate was added and stirring was maintained for 48 hours. The precipitate was recovered by filtration and was washed with water and then ether. The product was dried at 90°C in vacuo to give 6.26 g, 69% of white solid. Mp : 328-330°C.
2.22-[nitrogen-heterocyclic ring]-6-pyridin-4-ylpyrimidin-4(1 H)-one
A solution of 1 equivalent of 2-(methylthio)-6-pyridinyl-4-ylpyrimidin-4(1 H)-one and 3 to 5 equivalents of a [nitrogen-heterocyclic ring] of formula (V) were suspended in amyl alcohol (0.1 - 0.2 M) and was heated at 150°C during 72 hours.The cooled solution was concentrated and purified by chromatography on silica gel.
A list of chemical structures and physical data for compounds of the aforementioned formula (I) illustrating the present invention is given in the following tables.
Table 1 = 4-pyridyl, n=1
Figure imgf000022_0001
Figure imgf000022_0002
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Table 2
R1 = 4-pyridyl
Figure imgf000026_0001
Figure imgf000026_0002
All compounds are bases, except (*) = maleate and (**) = oxalate Table 3
Figure imgf000027_0001
(I) R1 = 4-pyridyl
Figure imgf000027_0002
Test Example: Inhibitory activity of the medicament of the present invention against GSK3β:
Two different protocols can be used.
In a first protocol : 7.5 μM of prephosphorylated GS1 peptide and 10 μM ATP (containing 300,000 cpm of 33P-ATP) were incubated in 25 mM Tris-HCI, pH 7.5, 0.6 mM DTT, 6 mM MgCI2, 0.6 mM EGTA, 0.05 mg/ml BSA buffer for 1 hour at room temperature in the presence of GSK3β (total reaction volume : 100 microliters).
In a second protocol : 4.1 μM of prephosphorylated GS1 peptide and 42 μM ATP (containing 260,000 cpm 33P-ATP) were incubated in 80 mM Mes-NaOH, pH 6.5, 1 mM Mg acetate, 0.5 mM EGTA, 5 mM 2-mercaptoethanol, 0.02% Tween 20, 10% glycerol buffer for 2 hours at room temperature in the presence of GSK3β. Inhibitors were solubilised in DMSO (final solvent concentration in the reaction medium, 1 %).
The reaction was stopped with 100 microliters of a solution made of 25 g polyphosphoric acid (85% P2O5), 126 ml 85% H3PO4, H2O to 500 ml and then diluted to 1 :100 before use. An aliquot of the reaction mixture was then transferred to Whatman P81 cation exchange filters and rinsed with the solution described above. Incorporated 33P radioactivity was determined by liquid scintillation spectrometry. The phosphorylated GS-1 peptide had the following sequence : NH2-YRRAAVPPSPSLSRHSSPHQS(P)EDEE-COOH.
The GSK3β inhibitory activity of the compounds of the present invention are expressed in IC50, and as an illustration the range of ICso's for the compound in the table 1 is between 0.1 to 10 micromolar concentrations. Formulation Example
(1) Tablets
The ingredients below were mixed by an ordinary method and compressed by using a conventional apparatus.
Compound of Example 1 30 mg
Crystalline cellulose 60 mg
Corn starch 100 mg
Lactose 200 mg Magnesium stearate 4 mg
(2) Soft capsules
The ingredients below were mixed by an ordinary method and filled in soft capsules. Compound of Example 1 30 mg
Olive oil 300 mg
Lecithin 20 mg
(1) Parenteral preparations
The ingredients below were mixed by an ordinary method to prepare injections contained in a 1 ml ampoule. Compound of Example 1 3 mg
Sodium chloride 4 mg Distilled water for injection 1 ml
Industrial Applicability
The compounds of the present invention have GSK3β inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activity of GSK3β and more particularly of neurodegenerative diseases.

Claims

What is claimed is:
1. A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof:
Figure imgf000030_0001
(I) wherein: R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a Cι_4 alkyl group, alkoxy group or a halogen atom;
f N represents a [nitrogen-heterocyclic ring] of formula X, Y or Z
Figure imgf000030_0002
X Y z
Wherein
R2 represents
* a C-6,10 aryl group, * a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or
* a C-ι-6 alkyl group substituted by 1 to 3 substituents selected from
- a hydroxyl group, - a C3.6 cycloalkyl group
- a Cβ.-io aryl group and
- a heterocyclic ring as defined above; n represents 1 or 2; Z being selected from the group consisting of
Figure imgf000031_0001
wherein R3 represents a hydrogen atom or a Cι_6 alkyl group;
the Cβ.io aryl groups and heterocyclic ring being optionally substituted by 1 to 3 substituents selected from a Cι.6 alkyl group, halogen atom, a C^ perhalogenated alkyl group, a Cι-3 halogenated alkyl group, a hydroxyl group, a Cι-e alkoxy group, methylenedioxy group, a nitro, a cyano or a phenyl group.
2. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 , wherein R1 represents an unsubstituted 4-pyridyl group.
3. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula X and R2 represents
* a C-6,10 aryl group,
* a heterocyclic ring having 1-4 hetero atoms selected from oxygen atom, sulfur atom, and nitrogen atom, and having total ring-constituting atoms of 5-10, or
* a C 1-6 alkyl group substituted by one Cβ o aryl group.
4. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula X and a) R2 represents a phenyl or substituted phenyl ring, a naphthyl or substituted naphthyl ring or a tetrahydronaphthyl or a substituted tetrahydronaphthyl ring, or b) R2 represents a heterocyclic ring selected from furopyridine ring, thienopyridine ring, imidazopyridine ring, pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, isoquinoline ring and pyrimidine ring; and more preferably furo[3,2-c]pyridine ring, thieno[3,2- c]pyridine ring, imidazo[4,5-c]pyridine ring, imidazo[1 ,2-a]pyridine ring, indole ring, indoline ring, indazole ring, benzimidazole ring, quinoline ring, isoquinoline ring, pyridine ring and pyrimidine ring, and / or c) n is 1.
5. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula Y and R2 represents a heterocyclic ring selected from a furan ring, imidazole ring, and indoline ring.
6. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein the [nitrogen-heterocyclic ring] is of formula Z and is selected from : 2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indole, 1 ,2,3,4-tetrahydroisoquinoline,
4,5,6,7-tetrahydrothieno[2,3-c]pyridine,and 1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine.
7. A pyrimidone derivative which is selected from the group consisting of: 2-[4-(2,5-dimethylphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one,
2-[4-(7-ethoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(7-methoxy-1 ,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]-6-pyridin-4- ylpyrimidin-4(1 H)-one,
2-[4-(4-methoxyphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1]H)-one, 2-[4-(4-chlorophenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(pyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(7-fluoronaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(7-propoxynaphth-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-[7-(2-methylethoxy)naphth-1-yl]piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)- one,
2-[4-(pyrimidin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(2-phenylphenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(phenylmethyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(phenyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-[3,4-(methylenedioxy)phenyl]piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(3-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(quinoiin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one,
2-[4-(imidazo[1 ,2-a]pyridin-5-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(1 H -indazol-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(5-methoxy-1H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(1 H-indazol-7-yl)piperazin-1-yl]-6-pyridin-4-yipyrimidin-4(1 H)-one,
2-[4-(4-methoxy-1 H-benzimidazol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin- 4(1 H)-one,
2-[4-(1 H-indol-5-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(6,7-dimethoxy-1 ,2,3,4-tetrahydronaphthalen-2-yl)piperazin-1-yl]-6-pyridin-4- ylpyrimidin-4(1 H)-one,
2-[4-(3-phenylpropyl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(isoquinolin-1-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(4-cyanopyridin-2-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-(2,3-dihydro-1 H-indol-7-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one. 2-[4-(1-methyl-1H-indol-3-yl)piperazin-1-yl]-6-pyridin-4-ylpyrimidin-4(1H)-one, 2-[4-[(4-methoxyphenyl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(2-phenylethyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-[hydroxy(furan-2-yl)methyl]piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(2-cyclohexylpropyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(1 H-imidazol-4-yl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(phenylmethyl)piperidin-1-yl]-6-pyridin-4-ylpyrimidin-4(1 H)-one, 2-[4-(1 H-indoi-3-yl)piperidin-1-yl]-6-pyridin-4-yipyrirnidin-4(1 H)-one, 2-[4-(indolin-5-yl)piperidinyl]-6-pyridin-4-ylpyrimidin-4(1 H)-one,
6-pyridin-4-yl-2-[2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indol-2-yl]pyrimidin-4(1 H)-one,
6-pyridin-4-yl-2-[1 ,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1 H)-one,
6-pyridin-4-yl-2-[6,7-dimethoxy-1 ,2,3,4-tetrahydroisoquinolin-2-yl]pyrimidin-4(1 H)- one,
6-pyridin-4-yl-2-[4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl]pyrimidin-4(1 H)-one and
6-pyridin-4-yl-2-[1 ,2,3,4-tetrahydrobenzofuro[2,3-c]pyridin-2-yl]pyrimidin-4(1H)- one, or a salt thereof, or a solvate thereof or a hydrate thereof.
8. A medicament comprising as an active ingredient a substance selected from the group consisting of a pyrimidone derivative according to claim 1.
9. A GSK3β inhibitor selected from the group of a pyrimidone derivative represented by formula (I) or salts thereof, or a solvate thereof or a hydrate thereof according to claim 1.
10. Use of a compound according to claim 1 for the preparation of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3β activity.
11. Use of a compound according to claims 1 to 7 for the preparation of a medicament for preventive and/or therapeutic treatment of a neurodegenerative disease.
12. Use of a compound according to claim 11, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies, vascular dementia; acute stroke, traumatic injuries; cerebrovascular accidents, brain cord trauma, spinal cord trauma; peripheral neuropathies; retinopathies or glaucoma.
13. Use of a compound according to claims 1 to 7 for the preparation of a medicament for preventive and/or therapeutic treatment of non-insulin dependent diabetes; obesity; manic depressive illness; schizophrenia; alopecia; or cancers.
14. Use according to claim 13 wherein cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia or virus-induced tumors.
PCT/EP2001/003639 2000-03-23 2001-03-22 2-[nitrogen-heterocyclic]pyrimidone derivatives WO2001070728A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001262150A AU2001262150A1 (en) 2000-03-23 2001-03-22 2-(nitrogen-heterocyclic)pyrimidone derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP00400801.7 2000-03-23
EP00400802.5 2000-03-23
EP00400802A EP1136489A1 (en) 2000-03-23 2000-03-23 2-[Piperidin-1-yl]pyrimidone derivatives
EP00400803.3 2000-03-23
EP00400803A EP1136493A1 (en) 2000-03-23 2000-03-23 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
EP00400801A EP1136483A1 (en) 2000-03-23 2000-03-23 2-[Piperazinyl]pyrimidone derivatives

Publications (1)

Publication Number Publication Date
WO2001070728A1 true WO2001070728A1 (en) 2001-09-27

Family

ID=27223599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003639 WO2001070728A1 (en) 2000-03-23 2001-03-22 2-[nitrogen-heterocyclic]pyrimidone derivatives

Country Status (2)

Country Link
AU (1) AU2001262150A1 (en)
WO (1) WO2001070728A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055007A1 (en) * 2002-12-16 2004-07-01 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
EP1454910A1 (en) * 2003-03-07 2004-09-08 Sanofi-Synthelabo Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP1454908A1 (en) * 2003-03-07 2004-09-08 Sanofi-Synthelabo Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
WO2004080977A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated 4-substituted-5-cyano-1h-pyrimidin-6-(thi)ones as gsk-3 inhibitors
WO2005007648A2 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
JP2006521370A (en) * 2003-03-26 2006-09-21 三菱ウェルファーマ株式会社 2,3,6-substituted-4-pyrimidone derivatives
US7256199B1 (en) 1998-09-25 2007-08-14 Mitsubishi Chemical Corporation Pyrimidone derivatives
JP2008509932A (en) * 2004-08-13 2008-04-03 ニューロジェン・コーポレーション Substituted biaryl piperazinyl-pyridine analogs
JP2008512347A (en) * 2004-09-09 2008-04-24 田辺三菱製薬株式会社 2-morpholino-4-pyrimidone compounds
WO2008078837A1 (en) * 2006-12-26 2008-07-03 Mitsubishi Tanabe Pharma Corporation 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors
US7427615B2 (en) 2001-09-21 2008-09-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
AU2004218249B2 (en) * 2003-03-07 2009-04-30 Mitsubishi Pharma Corporation Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
US7572793B2 (en) 2001-09-21 2009-08-11 Mitsubishi Tanabe Pharma Corporation 3-Substituted-4-pyrimidone derivatives
US20090233918A1 (en) * 2006-03-15 2009-09-17 Mitsubishi Tanabe Pharma Corporation 2-(cyclic amino)-pyrimidone derivatives
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2011525907A (en) * 2008-06-26 2011-09-29 田辺三菱製薬株式会社 Substituted tricyclic derivatives for neurodegenerative diseases
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US8741901B2 (en) 2004-07-15 2014-06-03 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2017533957A (en) * 2014-11-03 2017-11-16 イオメット ファーマ リミテッド Pharmaceutical compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
WO2000018758A1 (en) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Pyrimidone derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
WO2000018758A1 (en) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Pyrimidone derivatives

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256199B1 (en) 1998-09-25 2007-08-14 Mitsubishi Chemical Corporation Pyrimidone derivatives
US7572793B2 (en) 2001-09-21 2009-08-11 Mitsubishi Tanabe Pharma Corporation 3-Substituted-4-pyrimidone derivatives
US7427615B2 (en) 2001-09-21 2008-09-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2004055007A1 (en) * 2002-12-16 2004-07-01 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
KR100956052B1 (en) 2002-12-16 2010-05-06 미쓰비시 타나베 파마 코퍼레이션 3-substituted-4-pyrimidone derivatives
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
JP2006510684A (en) * 2002-12-16 2006-03-30 三菱ウェルファーマ株式会社 3-substituted-4-pyrimidone derivatives
EA009027B1 (en) * 2002-12-16 2007-10-26 Мицубиси Фарма Корпорейшн 3-substituted-4-pirimidone derivatives
AU2004218249B2 (en) * 2003-03-07 2009-04-30 Mitsubishi Pharma Corporation Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP1454910A1 (en) * 2003-03-07 2004-09-08 Sanofi-Synthelabo Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
CN100376576C (en) * 2003-03-07 2008-03-26 赛诺菲安万特 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP1454908A1 (en) * 2003-03-07 2004-09-08 Sanofi-Synthelabo Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
WO2004080977A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated 4-substituted-5-cyano-1h-pyrimidin-6-(thi)ones as gsk-3 inhibitors
US7217712B2 (en) 2003-03-12 2007-05-15 Vertex Pharmaceuticals Incorporated 4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3 inhibitors
US7504411B2 (en) 2003-03-26 2009-03-17 Mitsubishi Tanabe Pharma Corporation 2,3,6-Trisubstituted-4-pyrimidone derivatives
JP2006521370A (en) * 2003-03-26 2006-09-21 三菱ウェルファーマ株式会社 2,3,6-substituted-4-pyrimidone derivatives
EP2305651A1 (en) 2003-03-26 2011-04-06 Mitsubishi Tanabe Pharma Corporation 2,3,6-trisubstituted-4-pyrimidone derivatives
WO2005007648A3 (en) * 2003-07-16 2005-03-24 Neurogen Corp Biaryl piperazinyl-pyridine analogues
US7566712B2 (en) 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
WO2005007648A2 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
JP2007534624A (en) * 2003-07-16 2007-11-29 ニューロジェン・コーポレーション Biaryl piperazinyl-pyridine analogues
US9085531B2 (en) 2004-07-15 2015-07-21 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8741901B2 (en) 2004-07-15 2014-06-03 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7662830B2 (en) 2004-08-13 2010-02-16 Neurogen Corporation Substituted biaryl piperazinyl-pyridine analogues
JP2008509932A (en) * 2004-08-13 2008-04-03 ニューロジェン・コーポレーション Substituted biaryl piperazinyl-pyridine analogs
US8334382B2 (en) 2004-08-13 2012-12-18 Neurogen Corporation Substituted biaryl piperazinyl-pyridine analogues
JP2008512347A (en) * 2004-09-09 2008-04-24 田辺三菱製薬株式会社 2-morpholino-4-pyrimidone compounds
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8569294B2 (en) * 2006-03-15 2013-10-29 Mitsubishi Tanabe Pharma Corporation 2-(cyclic amino)-pyrimidone derivatives
US20090233918A1 (en) * 2006-03-15 2009-09-17 Mitsubishi Tanabe Pharma Corporation 2-(cyclic amino)-pyrimidone derivatives
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2382975A2 (en) 2006-05-09 2011-11-02 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008078837A1 (en) * 2006-12-26 2008-07-03 Mitsubishi Tanabe Pharma Corporation 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors
US8592417B2 (en) 2006-12-26 2013-11-26 Mitsubishi Tanabe Pharma Corporation 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
JP2010514670A (en) * 2006-12-26 2010-05-06 田辺三菱製薬株式会社 2-Substituted-6-heterocyclic pyrimidone derivatives
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2011525907A (en) * 2008-06-26 2011-09-29 田辺三菱製薬株式会社 Substituted tricyclic derivatives for neurodegenerative diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9173879B2 (en) 2009-05-12 2015-11-03 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US9604960B2 (en) 2009-05-12 2017-03-28 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2017533957A (en) * 2014-11-03 2017-11-16 イオメット ファーマ リミテッド Pharmaceutical compounds
JP2020125349A (en) * 2014-11-03 2020-08-20 イオメット ファーマ リミテッド Pharmaceutical compound
JP6994538B2 (en) 2014-11-03 2022-01-14 イオメット ファーマ リミテッド Pharmaceutical compound

Also Published As

Publication number Publication date
AU2001262150A1 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
WO2001070728A1 (en) 2-[nitrogen-heterocyclic]pyrimidone derivatives
EP1276738B1 (en) 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors
US7465737B2 (en) Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
US7608624B2 (en) 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
AU2007287319A1 (en) Pyrimidone compounds as GSK-3 inhibitors
KR20110082189A (en) Modulators of amyloid beta
WO2001070727A1 (en) 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
EP1460076A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1136483A1 (en) 2-[Piperazinyl]pyrimidone derivatives
NZ576773A (en) Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives
WO2001070726A1 (en) Aminophenyl pyrimidone derivatives
NO329756B1 (en) Imidazo [1,2-a] pyrimidone derivative, uses thereof, drug and GSK3beta inhibitor
EP1136484A1 (en) 2-(Arylalkylamino)pyrimidone derivatives
EP1136493A1 (en) 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
WO2001070725A1 (en) 2-[indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
EP1136489A1 (en) 2-[Piperidin-1-yl]pyrimidone derivatives
EP1136099A1 (en) 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors
EP1136491A1 (en) 2-[(Heteroaryl)alkylamino]pyrimidone derivatives
EP1340758A1 (en) Heteroaryl substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP